Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang 421001, China.
Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang 421001, China.
Clin Chim Acta. 2019 Jul;494:52-57. doi: 10.1016/j.cca.2019.03.006. Epub 2019 Mar 13.
CCN3 is a novel adipokine and has emerged as a potential metabolic regulator. However, information regarding the role of CCN3 in type 2 diabetes mellitus (T2DM) remains unclear. This study measured for the first time serum CCN3 levels in T2DM and explored the correlations between its serum levels and various metabolic parameters in humans.
A total of 219 newly diagnosed T2DM (nT2DM) patients and 205 healthy control subjects, matched for age and sex ratio, were enrolled. Circulating CCN3 and TNF-α, IL-6 and MCP-1 were measured by ELISA. The anthropometric assessment and biochemical evaluation were done in all subjects. OGTT were performed in 34 healthy individuals to investigate the association of CCN3 with glucose.
Serum CCN3 levels were significantly higher in nT2DM patients compared to those of the healthy controls (6.71[4.88, 8.56] vs. 4.51[3.55, 5.99] ng/ml, P < 0.01). Serum CCN3 positively correlated with BMI, WC, FAT%, TG, FPG, 2 h-PG, HbA1c, FIns, HOMA-IR, hs-CRP and TNF-α, IL-6 and MCP-1, but negatively with HOMA-β in all individuals (P < 0.05). Multiple linear regression analysis indicated that BMI, HOMA-IR, TNF-α and MCP-1 were independently associated with CCN3. Multivariate logistic regression analysis demonstrated that CCN3 was correlated with nT2DM. Finally, area under ROC curve of CCN3 (gender and age adjusted) for predicting the presence of nT2DM was 0.725(95% CI: 0.676-0.773). After an oral glucose challenge, there was no obvious change in the circulating levels of CCN3 as compared to 0 min (P > 0.05).
Elevation of CCN3 in nT2DM supports the hypothesis that CCN3 may serve as a risk factor associated with the pathogenesis of T2DM.
CCN3 是一种新型的脂肪因子，已成为潜在的代谢调节剂。然而，关于 CCN3 在 2 型糖尿病（T2DM）中的作用的信息尚不清楚。本研究首次测量了 T2DM 患者的血清 CCN3 水平，并探讨了其血清水平与人类各种代谢参数之间的相关性。
共纳入 219 例新诊断的 T2DM（nT2DM）患者和 205 例年龄和性别比例相匹配的健康对照者。采用 ELISA 法测定循环 CCN3 和 TNF-α、IL-6 和 MCP-1。所有受试者均进行人体测量学评估和生化评估。对 34 名健康个体进行 OGTT 以研究 CCN3 与葡萄糖的关系。
nT2DM 患者的血清 CCN3 水平明显高于健康对照组（6.71[4.88, 8.56]vs. 4.51[3.55, 5.99]ng/ml，P<0.01）。血清 CCN3 与 BMI、WC、FAT%、TG、FPG、2h-PG、HbA1c、FIns、HOMA-IR、hs-CRP 和 TNF-α、IL-6 和 MCP-1 呈正相关，但与所有个体的 HOMA-β呈负相关（P<0.05）。多元线性回归分析表明，BMI、HOMA-IR、TNF-α和 MCP-1 与 CCN3 独立相关。多元 logistic 回归分析表明，CCN3 与 nT2DM 相关。最后，CCN3 的 ROC 曲线下面积（性别和年龄校正）预测 nT2DM 的存在为 0.725（95%CI：0.676-0.773）。口服葡萄糖负荷后，与 0min 相比，循环 CCN3 水平无明显变化（P>0.05）。
nT2DM 中 CCN3 的升高支持 CCN3 可能作为与 T2DM 发病机制相关的危险因素的假说。
